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Abstract
Background: Chagas disease is one of the most important public health problems and a leading cause of cardiac failure in
Latin America. The currently available drugs to treat T. cruzi infection (benznidazole and nifurtimox) are effective in humans
when administered during months. AmBisome (liposomal amphotericin B), already shown efficient after administration for
some days in human and experimental infection with Leishmania, has been scarcely studied in T. cruzi infection.
Aims: This work investigates the effect of AmBisome treatment, administered in 6 intraperitoneal injections at various times
during acute and/or chronic phases of mouse T. cruzi infection, comparing survival rates and parasitic loads in several
tissues.
Methodology: Quantitative PCR was used to determine parasitic DNA amounts in tissues. Immunosuppressive treatment
with cyclophosphamide was used to investigate residual infection in tissues.
Findings: Administration of AmBisome during the acute phase of infection prevented mice from fatal issue. Parasitaemias
(microscopic examination) were reduced in acute phase and undetectable in chronic infection. Quantitative PCR analyses
showed significant parasite load reductions in heart, liver, spleen, skeletal muscle and adipose tissues in acute as well as in
chronic infection. An earlier administration of AmBisome (one day after parasite inoculation) had a better effect in reducing
parasite loads in spleen and liver, whereas repetition of treatment in chronic phase enhanced the parasite load reduction in
heart and liver. However, whatever the treatment schedule, cyclophosphamide injections boosted infection to parasite
amounts comparable to those observed in acutely infected and untreated mice.
Conclusions: Though AmBisome treatment fails to completely cure mice from T. cruzi infection, it impedes mortality and
reduces significantly the parasitic loads in most tissues. Such a beneficial effect, obtained by administrating it over a short
time, should stimulate studies on using AmBisome in association with other drugs in order to shorten recovery from T. cruzi
infection.
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Introduction
Chagas disease is a leading cause of cardiac failure and the most
important parasitic disease in terms of morbidity and mortality in
Latin America. Its causal agent, the protozoan parasite Trypano-
soma cruzi, belonging to the family of Trypanosomatidae, currently
infects 8 to 10 million persons. It is usually transmitted by the
faeces of bloodsucking insect vectors (Hemiptera Reduviidae), human-
to-human by infected blood products (and solid organ transplants),
and from mother-to-child [1–3]. Large-scale migration of Latin
Americans over the last few decades has contributed to Chagas
disease becoming a global health issue [4]. There is currently an
increased risk of transmission via infected blood products and/or
congenital transmission in non-endemic countries, particularly in
United States and Europe [5–8]. After an acute phase, generally
asymptomatic though sometimes fatal in children, the infection
evolves to an asymptomatic and silent chronic phase. Decades
after primary infection, 30 to 40% of infected individuals develop a
symptomatic chronic either cardiac (the most frequently encoun-
tered) and/or digestive clinical form of Chagas disease (megacolon
and/or megaoesophagus), responsible for an important morbi-
mortality [1,3].
The currently used trypanocidal drugs, benznidazole and
nifurtimox, were developed empirically in the 1960s and 1970s,
respectively. They are more effective in early acute infection than
in the late well established chronic phase. Though the lack of good
markers complicates the validation of parasitic cure, these drugs
appear preventing progression of cardiac chronic lesions [1,9–11].
However, such drugs have to be taken for 1 to 3 months and can
induce severe side effects conducing to stop the treatment [12].
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5Thus, the chemotherapy of Chagas disease remains an unsolved
problem, and alternative or novel drugs are needed. Numbers of
different compounds have been assayed in a variety of ways, even
though none emerged as a new efficient treatment [13,14].
The macrolide polyene amphotericin B is known to bind to
sterols of eukaryotic cell membranes, inducing alterations of cell
permeability and cell death. While amphotericin can bind to the
cholesterol component of mammalian cells, inducing cytotoxic
effects, it has a higher affinity for ergosterol, a component of the
fungal cell membrane, leading to their specific killing. To
minimize the toxic side-effects of amphotericin, a liposomal
formulation of this molecule named AmBisome has been
developed [15], and is a current and potent treatment of invasive
fungal infections with Candida and Aspergillus [16–18]. As
trypanosomatids also present ergosterol as component of their
membranes [19], AmBisome might also be effective against
infections with such parasites. Clinical trials have demonstrated
the high efficacy of AmBisome treatment in human visceral
leishmaniasis, leading to consider it as the first-line treatment for
this disease [20–24]. Although ergosterol is also the predominant
membrane sterol of T. cruzi [25,26], few data are currently
available on the effect of amphotericin on this parasite. Though
several studies showed its in vitro trypanocidal activity [27–33], only
one report described the in vivo effect of four amphotericin B
formulations in mice acutely infected with T. cruzi. This latter
study showed that a single dose of 25 mg/kg of AmBisome
suppresses acute infection (on the basis of blood microscopic
observations), whereas other amphotericin B lipid formulations
increased the survival rate but did not eradicate infection in all
animals [34].
On the basis of these results and aiming to obtain more
information on the efficacy of AmBisome as a potential drug for
Chagas disease, we have investigated thoroughly its effect in both
acute and chronic phasesofmouse T.cruzi infection.We have tested
various schemes of treatment and studied by quantitative PCR the
parasitic loads in several organs known to host parasite multiplica-
tion (heart, skeletal muscle, adipose tissue, spleen and liver).
Methods
Mice, infection and treatments
BALB/cJ mice were obtained from Janvier (Le Genest-St-Isle,
France) and were maintained in our animal facilities in compliance
with the guidelines of the ULB (Universite ´ Libre de Bruxelles)
Ethic Committee for the use of laboratory animals (protocol 51
approved by CEBEA, Brussels, Belgium). Mice were infected at 6
weeks-old by intra-peritoneal (i.p.) injection of 1,000 blood
trypomastigotes of the Tulahuen strain of T. cruzi (genotype TcVI;
[35]). Blood parasitaemias were regularly determined by micro-
scopic examination of tail vein blood, with a detection limit of
10,000 parasites/mL [36].
Mice were treated with 6 i.p. injections of AmBisome (Gilead,
Paris, France; 25 mg/kg) given on alternate days starting either on
the first day post-inoculation (dpi 1), during the acute parasitemic
phase (dpi 10), the chronic phase (dpi 45) or both phases of
infection. (dpi 10 and dpi 45). The tested dose (25 mg/kg) derived
from the previous report of Yardley et al. [34]. Schedules and doses
of AmBisome treatments, as well as mouse groups, are described in
Table 1. Some chronically-infected mice were submitted to
cyclophosphamide (Endoxan, Baxter, Belgium) immunosuppres-
sive treatment (4 i.p. injections of 200 mg/kg on alternate days) as
previously described [37].
Author Summary
Chagas disease is a leading cause of cardiac failure and the
most important parasitic disease in terms of morbidity and
mortality in Latin America. After an acute parasitaemic
phase, infection naturally evolves to a long chronic phase.
If the currently available trypanocidal drugs, benznidazole
and nifurtimox, are effective in recent infection, they have
to be administered during months and induce side effects.
AmBisome, an already safe patented lipid formulation of
amphotericin B, has been previously shown efficient using
short time administration in treating human and experi-
mental Leishmania (another Trypanosomatidae parasite)
and fungal infections. This report evaluates the effect of
AmBisome in mice infected with T. cruzi. Besides parasi-
tologic evaluation, quantitative PCR was used to evaluate
the parasite loads in tissues. Injections of AmBisome in
acute infection allowed survival of all animals and
drastically reduced the parasite loads in most tissues,
whereas its administration in chronic phase strongly
decreased the parasite loads in heart and liver, without
completely curing the animals. Such results should
encourage investigations on using AmBisome in associa-
tion with standard drugs in order to improve the
treatment of T. cruzi infection.
Table 1. Mouse groups and AmBisome treatment schedules.
Mouse Groups
a n Treatment in acute phase (dpi) Treatment in chronic phase (dpi) Cyclophosphamide administration (dpi)
NT 20 - - -
6- - 4 6200 mg/kg/dose (60–66)
TeA 16 6625 mg/kg/dose (1–11) - -
TA 19 6625 mg/kg/dose (10–20) - -
TAC 10 6625 mg/kg/dose (10–20) 6625 mg/kg/dose (45–55) -
46 625 mg/kg/dose (10–20) 6625 mg/kg/dose (45–55) 46200 mg/kg/dose (60–66)
TC 7- 6 625 mg/kg/dose (45–55) -
6- 6 625 mg/kg/dose (45–55) 46200 mg/kg/dose (60–66)
aMice were either non treated (NT) or treated (T) with AmBisome during the acute (A) and/or chronic (C) phases of infection by intraperitoneal injections (i.p.)o n
alternate days. Some mice of indicated groups received cyclophosphamide administred on alternate days from dpi 60. Data in brackets indicate the first and the last
post-inoculation day (dpi) of treatment.
doi:10.1371/journal.pntd.0001216.t001
T. cruzi-Infected Mice Treated with AmBisome
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On days 21 (acute infection) or 74 post-inoculation (chronic
infection), mice were bled out under gazeous anesthesia via retro-
orbital puncture and blood collected in citrated microtubes. Heart,
liver, spleen, thigh muscle, and white adipose tissue (dorsal
subcutaneous) were harvested after thoroughly flushing the entire
mouse body with PBS [38], in order to avoid contamination of
collected tissues with blood parasites. Blood and tissue samples
were aliquoted and stored at 280uC until DNA extraction.
DNA extraction
Organ pieces (50 mg) were disrupted using Magna Lyser
instrument (Roche Diagnostics, Brussels, Belgium) at 6,500 rpm
for 50 s in Green Beads tubes (Roche Applied Science, Brussels,
Belgium) containing 400 ml of DNA Tissue buffer (Mole Genetics
AS, Lysaker, Norway). Then 800 mg Proteinase K (Roche Applied
Science, Brussels, Belgium) were added to the disrupted samples,
and incubated for 4 h at 56uC. DNA extraction was performed on
200 mL of blood or organ digested samples using GeneMole
apparatus and DNA Blood/Tissue kits (Mole Genetics AS,
Lysaker, Norway), and eluted in 200 mL of GeneMole Elution
buffer, according to the manufacturer recommendations.
Generation of tissue standards for PCR
The standards for the quantitative PCR (qPCR) reactions were
generated from tissue homogenates of non-infected mice (50 mg of
heart, liver, spleen, skeletal muscle, adipose tissue, prepared as
mentioned above), to which 10
6 T. cruzi culture trypomastigotes
were added, as previously described [39]. DNA (from tissues
spiked with parasites), extracted as mentioned above, was serially
diluted with 25 mg/mL of DNA obtained from tissues without
added parasites. The 10-fold diluted prepared standards contained
DNA from 10
5 to 10
22 parasites equivalents per 50 ng of total
DNA. A standard curve was generated from these standards to
determine the DNA parasitic load in organs of infected mice.
Infected blood standards were prepared by 10-fold serial
dilutions of 500 mL of fresh mouse blood artificially spiked with
10
8 T. cruzi trypomastigotes, as already described [40]. DNA was
extracted from each dilution as described above and a standard
curve ranging from 2610
8 to 2610
21 parasites/mL (correspond-
ing to 2610
5 to 2610
24 parasite equivalents per assay) was
generated to determine the parasitic DNA load of infected mouse
blood.
Real-Time quantitative PCR
Real-time PCR was performed using a LightCyclerH 480 system
(Roche Diagnostics Brussels, Belgium) according to the manufac-
turer’s instructions. Reactions were performed in a 25 mL final
volume with either 160 nM T. cruzi 195-bp repeat DNA specific
primers (Invitrogen, Carlsbad, California) TcZ1 59-CGAGCTC-
TTGCCCACACGGGTGCT-39 and TcZ2 59-CCTCCAAGCA-
GCGGATAGTTCAGG-39 [41] or 160 nM GAPDH Forward
59-GACTTCAACAGCAACTCCCAC-39 and GAPDH Reverse
59-TCCACCACCCTGTTGCTGTA-39 (from RTPrimer Data-
base) and Perfecta SYBRGreen SuperMix (Quanta Biosciences,
Gaithersburg USA). Each PCR reaction contained 50 ng genomic
tissue DNA or 1 mL of eluted blood DNA. Amplification protocol
consisted in a denaturation phase at 95uC for 59 (RampRate
4.40uC/s), then 50 cycles of amplification (95uC3 9, (RampRate
4.40uC/s), 65uC1 9 (RampRate 2.20uC/s)). Fluorescence emission
was measured at the end of the elongation step. A melting curve
phase program was applied with a continuous fluorescence
measurement between 50uC and 95uC (RampRate 2.20uC/s).
The identity of the amplified products was checked by analysis of
the melting curve carried out at the end of amplification. Each
LightCycler run contained 2 negative controls (no DNA added to
the reaction), and each DNA sample was quantified in duplicate.
Duplicate values for each DNA sample were averaged and parasite
equivalent load was calculated automatically by plotting the CP
values against each standard of known concentration and
calculation of the linear regression line of this curve.
Normalization of parasite loads in tissues
To normalize the amount of tissue analyzed in each PCR
reaction, we choose a housekeeping gene (GAPDH) to correct the
intra-sample variations of the initial sample amount, DNA
recovery and/or sample loading. Normalization with an external
standard was possible because the amplification of T. cruzi
genomic and murine GAPDH sequences occurred with the same
efficiency (TcZ: 1.912; GAPDH: 1.930) [39]. For normalization,
the TcZ DNA value in each tissue sample was divided by the value
of the murine GAPDH DNA in the same sample.
Statistical analysis
Results were presented as means 6 SEM. Comparisons of
means between groups were performed using the Mann-Whitney
U-test. To assess differences between survival curves, a long rank
test of Kaplan-Meier was performed. All tests were performed
using Graph Pad software (Prism 5 version 5.02).
Results
Comparison of qPCR estimated- and microscopically
determined-parasitaemias in untreated T. cruzi-infected
mice
Infection of BALB/c mice with the Tulahuen strain of T. cruzi
resulted in an acute parasitaemic phase easily detectable by
standard microscopic examination from 12 to 30 days post-
inoculation (dpi), peaking at 3.861.5610
6 parasites/mL on dpi 21
(NT group, Fig. 1A). This acute phase led to the death of 30% of
infected animals (Fig. 1B). Afterwards, the infection evolved to a
chronic phase during which blood parasites became undetectable
by standard microscopic examination. However, when such
chronically infected mice received the immunosuppressive cyclo-
phosphamide drug, they displayed a drastic increase of their blood
parasite levels easily detectable by microscopic examination,
reaching 5.463.6610
6 parasites/mL (on day 14 after the first
cyclophosphamide injection), i.e. levels comparable to those
previously observed in acute phase (Fig. 1A).
Quantitative PCR determination of parasitic DNA and
parasitaemia determined by microscopic observation were statis-
tically correlated (R=0.953, P=0.0003) and levels estimated in
the acute phase of infection (on dpi 21) were close to those
determined by microscopic observation. qPCR analysis of blood
samples collected on dpi 74 (chronic phase) allowed the detection
of parasite DNA in all infected mice, corresponding to a mean
level of 3,38061,440 parasite equivalents/mL (NT group, Fig. 2A),
i.e. values under the detection limit of microscopic observation. In
chronically infected mice receiving cyclophosphamide, circulating
parasite DNA levels drastically increased to values corresponding
to 19.4610.7610
6 parasite equivalents/mL (NT group, Fig. 2A).
qPCR estimation of parasite loads in other tissues of
untreated T. cruzi-infected mice
Levels of parasite DNA in tissues of T. cruzi-infected mice are
shown in Fig. 2. On dpi 21 (acute phase), heart, spleen, skeletal
T. cruzi-Infected Mice Treated with AmBisome
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ranging between 6,220 and 108,000 equivalent parasites per 50 ng
of total DNA, while parasite DNA amount was particularly low in
liver (85.9618.6 parasite equivalents per 50 ng of DNA). On dpi
74 (chronic phase), parasite DNA amounts were roughly reduced
by 10-fold in liver, 100 fold in muscle and heart, 1,000 fold in
spleen and 5,000-fold in adipose tissue as compared to acute
phase. In both phases, skeletal muscle depicted the highest parasite
DNA load. Again, cyclophosphamide injections induced an
increase in parasite DNA levels by around 1,000 times in adipose
tissue, 100-fold in hepatic tissue and only 10-fold in cardiac, spleen
and skeletal muscular tissues.
Effect of AmBisome treatment administered in acute
phase on mortality and tissue parasite loads of T. cruzi-
infected mice
As shown in Fig. 1B, administration of AmBisome to acutely
infected mice (TA; dpi 10) prevented mice from fatal issue (P,0.05
as compared with untreated animals) and all treated mice survived
until the end of the experiment (74 dpi). This observation, along
with the fact that cell blood counts remained similar in treated and
untreated animals (data not shown), suggested the absence of
major toxic effects of treatment at the used dose.
As shown in Fig. 1A, microscopic observation of blood samples
showed acutely infected mice treated with AmBisome significantly
reducing their acute phase mean parasitaemias by 5 times, though
blood parasites remained detectable at dpi 21 in all mice (TA:
6.760.8610
5 parasites/mL; NT: 3.861.5610
6 parasites/mL;
P=0.015). qPCR analyses of blood samples of treated mice
showed a similar tendency to reduce by 4 times (not statistically
significant) parasite DNA amounts compared to those observed in
untreated mice (Fig. 2A, Table 2). By contrast, qPCR analyses of
spleen and adipose tissue showed AmBisome treatment reducing
their parasite loads by 449 to 1,361 as compared with NT mice,
whereas such reduction was only by 6 to 51 in the other tissues
(Fig. 2 B–F, Table 2).
We also evaluated the effect of AmBisome given during the
acute phase on tissue parasite loads in chronic phase. If
parasitaemia on dpi 74 remained microscopically undetectable
in AmBisome-treated mice, qPCR, detected similar blood parasite
DNA levels in TA mouse group and in untreated mice (NT,
Fig. 2A, Table 2). By contrast, all other tissues collected on dpi 74
from TA mice exhibited a significant reduction in parasite DNA
amounts compared with NT animals (by 437 in liver and 8 to 176
in the other tissues) (P,0.05, Fig. 2B–F; Table 2).
Effect of AmBisome treatment administered in both
acute and chronic phases, or in chronic phase alone, on
tissue parasite loads of mice infected with T. cruzi
Since AmBisome treatment given during the acute phase of
infection did not eliminate totally the parasites, experiments were
also performed adding a second round of treatment during chronic
phase to mice previously treated during the acute phase (TAC
group). In parallel, other mice received injections of AmBisome
only during the chronic phase of infection (TC). Treatment in
chronic phase consisted on 6 i.p. injections of 25 mg/kg on
alternate days starting on dpi 60.
TC mice showed blood parasite DNA amounts roughly similar
to those of NT animals, (dpi 74, Fig. 2A), whereas they displayed a
significant reduction of parasite DNA loads in all tested tissues
when compared to untreated mice (dpi 74, Fig. 2B–F, P,0.05).
Such reduction was stronger in liver and heart (dpi 74, Fig. 2B–C,
Table 2, P,0.05). When compared to TA group, TC mice did not
display major changes in tissue parasite DNA loads (dpi 74,
Fig. 2B–F, Table 2).
TAC mice also presented similar blood parasite DNA amounts
than NT and TA chronically infected mice (dpi 74, Fig. 2A).
However, this second round of AmBisome allowed a significant
reduction of parasite DNA loads in all other tested tissues when
compared to NT mice (dpi 74, Fig. 2B–F, P,0.05). These parasite
loads remained lower than one parasite equivalent per 50 ng tissue
DNA, except in muscular tissue. This double treatment scheme
significantly improved the effect previously observed in liver from
the TA group (dpi 74, Fig. 2C, P,0.05), as mentioned by the
calculated fold decreases (Table 2).
Effect of AmBisome treatment administered in early
acute phase on tissue parasite loads of mice infected
with T. cruzi
We also investigated whether an earlier administration (starting
on dpi 1) was able to improve the treatment efficiency of
Figure 1. Survival and course of T. cruzi infection in AmBisome -
treated BALB/c mice. BALB/c mice were i.p. inoculated with 1,000
blood trypomastigotes. NT: untreated mice; AmBisome was administred
either in early acute phase (TeA), in acute phase (TA), or in chronic
phase (TC). TAC mice treated by AmBisome during the acute and the
chronic phases of infection. (A) Parasitaemia determined by fresh blood
microscopic examination. AmB: AmBisome administration period, CP:
cyclophosphamide administration period. (B) Survival curve of T. cruzi-
infected mice.
doi:10.1371/journal.pntd.0001216.g001
T. cruzi-Infected Mice Treated with AmBisome
www.plosntds.org 4 June 2011 | Volume 6 | Issue 6 | e1216Figure 2. Tissue parasite amounts in AmBisome-treated mice. NT: untreated mice; AmBisome was administred either in early acute phase
(TeA), in acute phase (TA), or in chronic phase (TC). TAC mice treated by AmBisome during the acute and the chronic phases of infection. Organs were
collected either in acute phase (dpi 21) or in chronic phase (dpi 74) from mice having received or not cyclophosphamide (CP). Both TcZ and GAPDH
sequences were quantified individually for each DNA sample. The amounts of parasite DNA in samples were expressed in parasite equivalents per mL
of blood (A) or per 50 ng DNA for heart (B), liver (C), spleen (D), muscle (E) and adipose tissue (F). * denotes a significant difference with NT acute mice
group, # denotes a significant difference with NT chronic mice group, 1 denotes a significant difference between treatments, *, #, 1 P,0.05; **, ##,
11 P,0.01; ***, ###, 111 P,0.001.
doi:10.1371/journal.pntd.0001216.g002
T. cruzi-Infected Mice Treated with AmBisome
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parasitaemias (microscopic determination) compared to NT group
(dpi 21, TeA: 4.8860.82610
5;P ,0.05). Comparison of qPCR
analyses performed in TeA and NT mice (on dpi 21) showed such
early treatment lowering parasite loads in all tissues (Table 2;
P,0.01 except for blood), the more potent effect being observed in
spleen. Interestingly, early treatment starting on dpi 1 had more
pronounced effect than that starting on dpi 10 in reducing parasite
loads in spleen and liver (by 6 to 8 fold; P,0.01), similar effect on
muscle. However, in adipose tissue the reducing effect of the early
AmBisome treatment (TeA) was less pronounced than in TA mice
(P,0.01). The potential long term effect of such early treatment
was also investigated by determining the tissue parasite loads on
dpi 74. Excepted for adipose tissue, the latter were decreased by 7
to 113 fold as compared to NT group, as indicated by the
calculated fold decreases (Table 2).
Effect of cyclophosphamide administration in T. cruzi-
infected mice treated with AmBisome
As reported in Fig. 1A–2A, a drastic increase of blood parasite
levels was observed 14 days after the first cyclophosphamide
injection (7 days after the 4
th injection) in all TC and TAC
AmBisome-treated mice, both by microscopical and qPCR
analyses, reaching parasite amounts comparable to that observed
in acutely infected NT mice. We also observed that cyclophos-
phamide injections similarly boosted parasite DNA levels in tissues
of all of these mice, as in NT mice (Fig. 2B–F). Such drastic
reactivation of parasite multiplication clearly showed that animals
were not completely cured from T. cruzi infection.
Cyclophosphamide immunosuppression test was not applied to
TA and TeA mouse groups, since at the end of AmBisome
treatment in acute phase, parasites were still observable in blood
by standard microscopic examination, indicating they were not
completely cured (see above; Fig. 1A).
Discussion
Taken together, these results indicate that AmBisome, at the
used doses (i.p. administration), prevents mice from fatal issue in
the acute phase of infection, contributes to drastically reduce
parasite loads in heart, liver, spleen, skeletal muscle and adipose
tissues in acute, as well as in chronic infection, but fails to
completely cure animals from T. cruzi infection. An earlier
administration of AmBisome (on dpi 1) has a better effect in
reducing parasite loads in spleen and liver in acute phase, whereas
repetition of treatment in chronic phase improves the reduction of
parasite loads in heart and liver.
Survival rate and parasitaemias (microscopic examination)
observed in untreated mice are in agreement with our previous
report using the same mouse and parasite strains [42,43]. Our
qPCR data obtained in tissues/organs from infected mice can be
considered as reliable since possible contaminations by DNA from
blood trypomastigotes have been drastically reduced by flushing
the entire circulatory system of mice. Moreover, such data agree
with those of previous works exploring T. cruzi infection in adipose
or muscular tissues of mice by normalised qPCR [39,44]. The high
amount of parasite DNA observed in skeletal muscle and heart
both in acute and chronic infection can be explained by the known
muscular tropism of the used parasite strain (TcVI genotype; [45]).
The lowest amount detected in liver likely relates to the
involvement of this organ as a major site of immunological
elimination of parasites [46]. The high amount of parasite DNA in
mouse adipose tissue also confirms previous reports [44]. The
more important effect of dpi 10 (TA)- vs. dpi 1-treatment (TeA) in
reducing parasite DNA in adipose tissue might indicate a later
parasite invasion of this tissue compared to others.
The comparisons of tissue parasitic loads through the course of
infection indicate that the AmBisome treatment initiated in acute
phase (TeA and TA) induces a global decrease of parasitic loads in
all studied organs, and that this beneficial effect is long-lasting
since still observed in chronic phase. The treatment given in
chronic phase only (TC) has also a significant beneficial effect in
reducing such organ parasitic loads. However, treatment repeated
in acute and chronic phases (TAC) does not present a significant
advantage over TC treatment. However, considering blood, if a
significant reduction of parasitaemia (microscopic determination)
can be observed after the acute phase treatments (TeA and TA),
the estimations of parasite DNA in chronic phase (qPCR
determination) remain similar in NT and treated mice, whatever
the scheduled treatments. This latter observation might relate to a
release of T. cruzi DNA into blood circulation, subsequent to an
intra-tissue lysis of parasites by AmBisome. Such parasitic DNA
release probably also occurs in acute phase. However, during this
phase, high levels of inflammatory molecules, such as the serum
amyloid P protein (SAP), are abundantly produced in response to
T. cruzi infection [47]. SAP is known to capture DNA and be
rapidly eliminated in liver [48,49], which might contribute to
decrease the detectable circulating DNA levels in acute, but not in
chronic phase. This indicates that qPCR determination of
parasitic DNA in blood does not reflect the actual parasitic load
in other tissues and is not sufficient enough to appreciate the effect
of a treatment.
Our results confirm that AmBisome treatment increases the
survival rate of acutely infected animals, although it does not cure
them, even if multiple injections of drug are used instead of only
one as previously indicated [34], and if treatment is started close to
inoculation date. Indeed, treated mice still displayed low levels of
parasites or parasite DNA in blood and other tissues both in early
(on dpi 21) as well as in late infection (on dpi 74). Our experiments
with the cyclophosphamide immunosuppressive drug confirm the
presence of residual tissue infection in various organs. The lack of
complete curative activity of the drug might be related to a sub-
estimation of its efficacy since it has been administered by i.p.
instead of intravenous route, known to be more effective for
diffusing liposome-encapsulated drugs [18,34]. Amphotericin B is
known to induce an immediate lysis of Trypanosomatidae parasitic
protozoa whatever their strain [50], due to the interaction of its
large macrolactone ring with ergosterol and other 24-alkyl sterols
Table 2. Reductions of DNA parasite loads in organs of
AmBisome-treated mice.
Acute
dpi
Phase
21
Chronic
dpi
Phase
74
Tissues TeA TA TeA TA TC TAC
Heart 14 11 54 176 293 353
Liver 39 6 113 437 660 1835
Spleen 3473 449 7 31 99 45
Muscle 69 51 103 37 19 68
Adipose
Tissue
77 1361 #1 8 104 15
Blood 64 #1 #1 #1 #1
For each mouse group, reduction ratios are expressed in fold decrease
compared to the mean of NT group.
doi:10.1371/journal.pntd.0001216.t002
T. cruzi-Infected Mice Treated with AmBisome
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pores. Consequently, another possible explanation for the absence
of complete curative effect might relate to the preferential tropism
of the used parasite strain (TcVI) for muscle tissues (see above),
whereas the AmBisome targeting, by its liposomal formulation, is
more directed toward liver, spleen and lungs [51,52]. So, the
present results do not exclude a more pronounced curative effect
using intravenous administration, or in T. cruzi infection with other
parasite strains having different tissue distribution. Moreover, a
beneficial effect of AmBisome treatment might be also expected in
T. cruzi congenital infection, in which parasites are preferentially
targeted to the liver by the fetal circulation [2,53], since our results
show the early treatment being able to reduce drastically parasite
loads in liver and spleen, in addition to allowing survival of all
infected animals.
Another information derived from the present study is the
significant reduction of DNA parasite load observed in tissues
(notably in cardiac tissue) of mice treated during the chronic phase
of infection. This phase is frequently encountered in human T.
cruzi infection and cumulative data indicate that treatment of such
infected subjects with the standard benznidazole drug significantly
reduce the progression of cardiac Chagas disease and increase the
frequency of negative seroconversion [11]. This could stimulate
studies on using association of drugs including AmBisome
(requiring only some injections) in T. cruzi- infected patients, in
order to improve and/or accelerate such beneficial evolution and
definitive cure.
Acknowledgments
We thank Dr. Carl de Trez (Laboratoire de Parasitologie, ULB, Belgique)
for his critical review of the manuscript.
Author Contributions
Conceived and designed the experiments: SC NC CT YC. Performed the
experiments: SC NC. Analyzed the data: SC NC CT YC. Wrote the
paper: SC NC CT YC.
References
1. Carlier Y, Pinto Dias JC, Ostermayer Luquetti A, Hontebeyrie M, Truyens C
(2002) Trypanosomiase ame ´ricaine ou maladie de Chagas. Encyclope ´die
Me ´dico-Chirurgicale. pp 1–21.
2. Carlier Y, Truyens C (2010) Maternal-Fetal Transmission of Trypanosoma
cruzi. In: Telleria J, Tibayrenc M, eds. American Trypanosomiasis, Chagas
Disease: One Hundred Years of Research ELSEVIER. pp 539–581.
3. Rassi A, Jr., Rassi A, Marin-Neto JA (2010) Chagas disease. Lancet 375:
1388–1402.
4. Coura JR, Vin ˜as PA (2010) Chagas disease : a new worldwide challenge. Nature
465: S6–S7.
5. Bern C, Montgomery SP (2009) An estimate of the burden of Chagas disease in
the United States. Clin Infect Dis 49: e52–e54.
6. Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, et al. (2008)
Mother-to-child transmission of Chagas’ disease in North America: why don’t
we do more? Matern Child Health J 12: 283–286.
7. Gascon J, Bern C, Pinazo MJ (2009) Chagas disease in Spain, the United States
and other non-endemic countries. Acta Trop.
8. Lescure FX, Canestri A, Melliez H, Jaureguiberry S, Develoux M, et al. (2008)
Chagas disease, France. Emerg Infect Dis 14: 644–646.
9. Croft SL, Barrett MP, Urbina JA (2005) Chemotherapy of trypanosomiases and
leishmaniasis. Trends Parasitol 21: 508–512.
10. Sosa-Estani S, Segura EL (2006) Etiological treatment in patients infected by
Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 19:
583–587.
11. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, et al. (2006) Long-term
cardiac outcomes of treating chronic Chagas disease with benznidazole versus no
treatment: a nonrandomized trial. Ann Intern Med 144: 724–734.
12. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, et al. (2009) Side effects of
benznidazole as treatment in chronic Chagas disease: fears and realities. Expert
Rev Anti Infect Ther 7: 157–163.
13. Ribeiro I, Sevcsik AM, Alves F, Diap G, Don R, et al. (2009) New, improved
treatments for Chagas disease: from the R&D pipeline to the patients. PLoS
Negl Trop Dis 3: e484.
14. Urbina JA (2010) Specific chemotherapy of Chagas disease: relevance, current
limitations and new approaches. Acta Trop 115: 55–68.
15. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ (1992)
Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.
Clin Pharmacokinet 23: 279–291.
16. Chen SC, Sorrell TC (2007) Antifungal agents. Med J Aust 187: 404–409.
17. Moen MD, Lyseng-Williamson KA, Scott LJ (2009) Liposomal amphotericin B:
a review of its use as empirical therapy in febrile neutropenia and in the
treatment of invasive fungal infections. Drugs 69: 361–392.
18. Takemoto K, Yamamoto Y, Ueda Y (2006) Evaluation of antifungal
pharmacodynamic characteristics of AmBisome against Candida albicans.
Microbiol Immunol 50: 579–586.
19. Roberts CW, McLeod R, Rice DW, Ginger M, Chance ML, et al. (2003) Fatty
acid and sterol metabolism: potential antimicrobial targets in apicomplexan and
trypanosomatid parasitic protozoa. Mol Biochem Parasitol 126: 129–142.
20. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, et al. (2006)
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect
Dis 43: 917–924.
21. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral
leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev
Microbiol 5: 873–882.
22. Cruz I, Chicharro C, Nieto J, Bailo B, Canavate C, et al. (2006) Comparison of
new diagnostic tools for management of pediatric Mediterranean visceral
leishmaniasis. J Clin Microbiol 44: 2343–2347.
23. Minodier P, Robert S, Noel G, Blanc P, Retornaz K, et al. (2005) [First-line
liposomal amphotericin B for pediatric visceral leishmaniasis in southern
France]. Arch Pediatr 12: 1102–1108.
24. Mondal S, Bhattacharya P, Ali N (2010) Current diagnosis and treatment of
visceral leishmaniasis. Expert Rev Anti Infect Ther 8: 919–944.
25. Hunt RC, Ellar DJ (1974) Isolation of the plasma membrane of a
trypanosomatid flagellate: general characterisation and lipid composition.
Biochim Biophys Acta 339: 173–189.
26. Urbina JA (2009) Ergosterol biosynthesis and drug development for Chagas
disease. Mem Inst Oswaldo Cruz 104 Suppl 1: 311–318.
27. Abitbol H, Pattini RE, Salvador J (1960) [The ‘‘in vitro’’ action of amphotericin
B on Trypanosoma cruzi.]. Rev Soc Argent Biol 36: 41–44.
28. Croft SL, Walker JJ, Gutteridge WE (1988) Screening of drugs for rapid activity
against Trypanosoma cruzi trypomastigotes in vitro. Trop Med Parasitol 39:
145–148.
29. de Castro SL, Soeiro MN, Higashi KO, Meirelles MN (1993) Differential effect
of amphotericin B on the three evolutive stages of Trypanosoma cruzi and on
the host cell-parasite interaction. Braz J Med Biol Res 26: 1219–1229.
30. Haido RM, Barreto-Bergter E (1989) Amphotericin B-induced damage of
Trypanosoma cruzi epimastigotes. Chem Biol Interact 71: 91–103.
31. Haido RM, Esteves MJ, Barreto-Bergter E (1992) Amphotericin B-induced
carbohydrate changes on the Trypanosoma cruzi surface membrane. J Protozool
39: 609–612.
32. Horvath AE, Zierdt CH (1974) The effect of amphotericin B on Trypanosoma
cruzi in vitro and in vivo. J Trop Med Hyg 77: 144–149.
33. Rolon M, Seco EM, Vega C, Nogal JJ, Escario JA, et al. (2006) Selective activity
of polyene macrolides produced by genetically modified Streptomyces on
Trypanosoma cruzi. Int J Antimicrob Agents 28: 104–109.
34. Yardley V, Croft SL (1999) In vitro and in vivo activity of amphotericin B-lipid
formulations against experimental Trypanosoma cruzi infections. Am J Trop
Med Hyg 61: 193–197.
35. Zingales B, Andrade SG, Briones MR, Campbell DA, Chiari E, et al. (2009) A
new consensus for Trypanosoma cruzi intraspecific nomenclature: second
revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz 104:
1051–1054.
36. Talliaferro WH, Pizzi T (1955) Connective tissue reactions in normal and
immunized mice to a reticulotropic strain of T. cruzi. J Infect Dis 96: 199–226.
37. Bustamante JM, Bixby LM, Tarleton RL (2008) Drug-induced cure drives
conversion to a stable and protective CD8+ T central memory response in
chronic Chagas disease. Nat Med 14: 542–550.
38. Ye X, Ding J, Zhou X, Chen G, Liu SF (2008) Divergent roles of endothelial
NF-kappaB in multiple organ injury and bacterial clearance in mouse models of
sepsis. J Exp Med 205: 1303–1315.
39. Cummings KL, Tarleton RL (2003) Rapid quantitation of Trypanosoma cruzi
in host tissue by real-time PCR. Mol Biochem Parasitol 129: 53–59.
40. Virreira M, Martinez S, Alonso-Vega C, Torrico F, Solano M, et al. (2006)
Amniotic fluid is not useful for diagnosis of congenital Trypanosoma cruzi
infection. Am J Trop Med Hyg 75: 1082–1084.
41. Virreira M, Truyens C, Alonso-Vega C, Brutus L, Jijena J, et al. (2007)
Comparison of Trypanosoma cruzi lineages and levels of parasitic DNA in
infected mothers and their newborns. Am J Trop Med Hyg 77: 102–106.
T. cruzi-Infected Mice Treated with AmBisome
www.plosntds.org 7 June 2011 | Volume 6 | Issue 6 | e121642. Carlier Y, Rivera MT, Truyens C, Puissant F, Milaire J (1987) Interactions
between chronic murine Trypanosoma cruzi infection and pregnancy: fetal
growth retardation. Am J Trop Med Hyg 37: 534–540.
43. Carlier Y, Rivera MT, Truyens C, Goldman M, Lambert P, et al. (1987)
Pregnancy and humoral immune response in mice chronically infected by
Trypanosoma cruzi. Infect Immun 55: 2496–2501.
44. Combs TP, Nagajyothi, Mukherjee S, de Almeida CJ, Jelicks LA, et al. (2005)
The adipocyte as an important target cell for Trypanosoma cruzi infection. J Biol
Chem 280: 24085–24094.
45. Andrade SG, Magalhaes JB, Pontes AL (1985) Evaluation of chemotherapy with
benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of
different types. Bull World Health Organ 63: 721–726.
46. Sardinha LR, Mosca T, Elias RM, do Nascimento RS, Goncalves LA, et al.
(2010) The liver plays a major role in clearance and destruction of blood
trypomastigotes in Trypanosoma cruzi chronically infected mice. PLoS Negl
Trop Dis 4: e578.
47. Scharfstein J, Barcinski MA, Leon LL (1982) Induction of the acute-phase
protein serum amyloid P in experimental Chagas’ disease. Infect Immun 35:
46–51.
48. Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, et al. (1999)
Serum amyloid P component controls chromatin degradation and prevents
antinuclear autoimmunity. Nat Med 5: 694–697.
49. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB (1994) The pentraxins, C-
reactive protein and serum amyloid P component, are cleared and catabolized
by hepatocytes in vivo. J Clin Invest 94: 1390–1396.
50. Ramos H, Valdivieso E, Gamargo M, Dagger F, Cohen BE (1996)
Amphotericin B kills unicellular leishmanias by forming aqueous pores
permeable to small cations and anions. J Membr Biol 152: 65–75.
51. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G (1990) Amphotericin B:
delivery systems. Antimicrob Agents Chemother 34: 381–384.
52. Hiemenz JW, Walsh TJ (1996) Lipid formulations of amphotericin B: recent
progress and future directions. Clin Infect Dis 22 Suppl 2: S133–S144.
53. Kiserud T (2005) Physiology of the fetal circulation. Semin Fetal Neonatal Med
10: 493–503.
T. cruzi-Infected Mice Treated with AmBisome
www.plosntds.org 8 June 2011 | Volume 6 | Issue 6 | e1216